Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana
Abstract
:1. Introduction
2. Materials and Methods
2.1. Study Design, Population, and Data Gathering Tools
2.2. Assessment Methods
2.2.1. Otoscopic Examination
2.2.2. Puretone Audiometry (PTA)
2.2.3. Otoacoustic Emissions
2.3. Statistical Analysis
2.4. Safety and Ethical Considerations
3. Results
3.1. Demographic Characteristics of the Study Participants
3.2. Clinical Characteristics of Treatment Group
3.3. Distribution of Audiometric Data
3.3.1. Distribution of Maximum and Minimum Pure Tone AC and BC Thresholds
3.3.2. Degrees of Hearing Loss in the Treatment and Control Groups
3.3.3. Distribution of OAE Results
3.4. Differences in the Treatment and Control Groups
3.5. Association between the Audiometry Findings and Exposure to TB Medications
4. Discussion
5. Conclusions
6. Limitations
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- WHO 2018. Available online: https://www.who.int/deafness/world-hearing-day/World-Hearing-Day-Infographic-EN.pdf?ua=1 (accessed on 16 October 2018).
- Amedofu, G.K.; Ocansey, G.; Antwi, B.B. Characteristics of hearing-impairment among patients in Ghana. Afr. J. Health Sci. 2006, 13, 110–116. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Awuah, P.; Duah, I.M.; Amedofu, G.K. Prevalence of hearing loss in patients with acute otitis media. J. Sci. Technol. 2012, 32, 11–17. [Google Scholar] [CrossRef]
- Nyako, E.A. Prevalence of Hearing Impairment at the Korle-Bu Teaching Hospital. Master’s Thesis, University of Ghana-Legon, Accra, Ghana, 2013; pp. 47–71. [Google Scholar]
- Larsen-Reindorf, R.; Otupiri, E.; Anomah, J.; Edwards, B.; Frimpong, B.; Waller, B.; Basura, G. Paediatric hearing loss: A community-based survey in peri-urban Kumasi, Ghana. J. Laryngol. Otol. 2019, 133, 796–804. [Google Scholar] [CrossRef] [PubMed]
- Kegele, J.; Hurth, H.; Lackner, P.; Enimil, A.; Sylverkin, J.; Ansong, D.; Nkyi, C.; Bonsu, B.; Agbenyega, T.; Schartinger, V.H.; et al. Otoacoustic emission testing in Ghanaian children with sickle-cell disease. Trop. Med. Int. Health 2015, 20, 1209–1212. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Amedofu, G.K. Hearing-impairment among workers in a surface gold mining company in Ghana. Afr. J. Health Sci. 2002, 9, 91–97. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zakpala, R.N.; Armah, F.A.; Sackey, B.M.; Pabi, O. Night-time decibel hell: Mapping noise exposure zones and individual annoyance ratings in an urban environment in Ghana. Scientifica 2014, 2014, 892105. [Google Scholar] [CrossRef] [Green Version]
- WHO. Tuberculosis. WHO; World Health Organization. 2018. Available online: http://www.who.int/mediacentre/factsheets/fs104/en/ (accessed on 11 August 2018).
- Agyeman, A.A.; Ofori-Asenso, R. Tuberculosis—an overview. J. Public Health Emerg. 2017, 1, 7. [Google Scholar] [CrossRef]
- Törün, T.; Güngör, G.; Özmen, Y.; Maden, E.; Bıçakçı, B.; Ataç, G.; Sevim, T. Side effects associated with the treatment of multidrug-resistant tuberculosis. Int. J. Tuberc. Lung Dis. 2005, 9, 1373–1377. [Google Scholar]
- Gülbay, B.E.; Gürkan, Ö.U.; Yildiz, Ö.A.; Önen, Z.P.; Erkekol, F.O.; Baççioǧlu, A.; Acican, T. Side effects due to primary antituberculosis drugs during the initial phase of therapy in 1149 hospitalized patients for tuberculosis. Respir. Med. 2006, 100, 1834–1842. [Google Scholar] [CrossRef] [Green Version]
- Yang, T.W.; Park, H.O.; Jang, H.N.; Yang, J.H.; Kim, S.H.; Moon, S.H.; Byun, J.H.; Lee, C.E.; Kim, J.W.; Kang, D.H. Side effects associated with the treatment of multidrug-resistant tuberculosis at a tuberculosis referral hospital in South Korea: A retrospective study. Medicine 2017, 96, e7482. [Google Scholar] [CrossRef]
- Rybak, L.P.; Ramkumar, V. Ototoxicity. Kidney Int. 2007, 72, 931. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Awofeso, N. Anti-tuberculosis medication side-effects constitute major factor for poor adherence to tuberculosis treatment. Bull. World Health Organ. 2008, 86, B–D. [Google Scholar] [CrossRef] [PubMed]
- BSA. Pure-Tone Air-Conduction and Bone-Conduction Threshold Audiometry with and without Masking. British Society of Audiology. 2018. Available online: https://www.bshaa.org/bsa-procedure-for-pure-tone-air-conduction-and-bone-conduction-threshold-audiometry-with-and-without-masking/ (accessed on 17 September 2019).
- Swanepoel, D.W.; Laurent, C. Open Access Guide to Audiology and Hearing Aids for Otolaryngologists- Classification of Hearing Loss. Developing World ENT. 2017. Available online: https://vula.uct.ac.za/access/content/group/27b5cb1b-1b65-4280- (accessed on 11 August 2018).
- Kemp, R.J.; Bankaitis, A.E. Infection control for audiologists. In Audiology: Practice Management; Hosford-Dunn, H., Roeser, R., Balente, M., Eds.; Thiem Medical Publishing: New York, NY, USA, 2000; Volume 3, pp. 257–279. [Google Scholar]
- Duggal, P.; Sarkar, M. Audiologic monitoring of multi-drug resistant tuberculosis patients on aminoglycoside treatment with long term follow-up. BMC Ear. 2007, 7, 5. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Javaid, A.; Khan, M.A.; Mehreen, S.; Jan, F.; Khan, M.A.; Ullah, I.; Nasir, M.; Ullah, U.; Khan, A.; Nazar, Z. Ototoxicity among patients receiving Multidrug-Resistant tuberculosis treatment; Experience from a tertiary care hospital. Pak. J. Chest Med. 2018, 23, 31–38. [Google Scholar]
- De Jager, R.; Van Altena, R. Hearing loss and nephrotoxicity in long-term aminoglycoside treatment in patients with tuberculosis. Int. J. Tuberc. Lung Dis. 2002, 6, 622–627. [Google Scholar]
- Sturdy, A.; Goodman, A.; Joś, R.J.; Loyse, A.; O’Donoghue, M.; Kon, O.M.; Dedicoat, M.J.; Harrison, T.S.; John, L.; Lipman, M.; et al. Multidrug-resistant tuberculosis (MDR-TB) treatment in the UK: A study of injectable use and toxicity in practice. J. Antimicrob. Chemother. 2011, 66, 1815–1820. [Google Scholar] [CrossRef] [Green Version]
- Vasconcelos, K.A.; Lima, M.A.; Frota, S.; Ruffino, N.A.; Kritski, A.L. Audiometric evaluation of patients treated for pulmonary tuberculosis. J. Bras. De Pneumol. 2012, 38, 81. [Google Scholar] [CrossRef] [Green Version]
- Peloquin, C.A.; Berning, S.E.; Nitta, A.T.; Simone, P.M.; Goble, M.; Huitt, G.A.; Iseman, M.D.; Cook, J.L.; Curran-Everett, D. Aminoglycoside Toxicity: Daily versus Thrice-Weekly Dosing for Treatment of Mycobacterial Diseases. Clin. Infect. Dis. 2004, 38, 1538–1544. [Google Scholar] [CrossRef]
- Ramma, L.; Ibekwe, T.S. Cochleo-vestibular clinical findings among drug resistant Tuberculosis Patients on therapy-a pilot study. Int. Arch. Med. 2012, 5, 3. [Google Scholar] [CrossRef] [Green Version]
- Sagwa, E.L.; Ruswa, N.; Mavhunga, F.; Rennie, T.; Leufkens, H.G.M.; Mantel-Teeuwisse, A.K. Comparing amikacin and kanamycin-induced hearing loss in multidrug-resistant tuberculosis treatment under programmatic conditions in a Namibian retrospective cohort. BMC Pharmacol. Toxicol. 2015, 16, 36. [Google Scholar] [CrossRef] [Green Version]
- Ibekwe, M.U.; Nwosu, C. Pure tone audiometric findings in patients on second-line treatment for multidrug-resistant tuberculosis. Port Harcourt Med. J. 2016, 10, 97. [Google Scholar] [CrossRef]
- Sogebi, O.A.; Fadeyi, M.O.; Adefuye, B.O.; Soyinka, F.O. Hearing thresholds in patients with drug-resistant tuberculosis: Baseline audiogram configurations and associations. J. Bras. De Pneumol. 2017, 43, 195–201. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Schacht, J. Mechanisms for Aminoglycoside Ototoxicity: Basic Science Researcher. In Ototoxicity; Roland, P., Rutka, J., Eds.; BC Decker, Inc.: Hamilton, ON, Canada, 2004; pp. 93–100. [Google Scholar]
- Huth, M.E.; Ricci, A.J.; Cheng, A.G. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int. J. Otolaryngol. 2011, 2011, 937861. [Google Scholar] [CrossRef] [Green Version]
- Huy, P.T.B.; Bernard, P.; Schacht, J. Kinetics of gentamicin uptake and release in the rat. Comparison of inner ear tissues and fluids with other organs. J. Clin. Investig. 1986, 77, 1492–1500. [Google Scholar]
- Hashino, E.; Shero, M. Endocytosis of aminoglycoside antibiotics in sensory hair cells. Brain Res. 1995, 704, 135–140. [Google Scholar] [CrossRef]
- Hiel, H.; Erre, J.-P.; Aurousseau, C.; Bouali, R.; Dulon, D.; Aran, J.-M. Gentamicin uptake by cochlear hair cells precedes hearing impairment during chronic treatment. Audiology 1993, 32, 78–87. [Google Scholar] [CrossRef] [PubMed]
- Barclay, M.L.; Begg, E.J. Aminoglycoside toxicity and relation to dose regimen. Advers. Drug React. Toxicol. Rev. 1994, 13, 207–234. [Google Scholar]
- Guthrie, O.W. Aminoglycoside induced ototoxicity. Toxicology 2008, 249, 91–96. [Google Scholar] [CrossRef]
- Karasawa, T.; Steyger, P.S. Intracellular mechanisms of aminoglycoside-induced cytotoxicity. Integr. Biol. Quant. Biosci. Nano Macro 2011, 3, 879–886. [Google Scholar] [CrossRef] [Green Version]
- Tabuchi, K.; Nishimura, B.; Nakamagoe, M.; Hayashi, K.; Nakayama, M.; Hara, A. Ototoxicity: Mechanisms of cochlear impairment and its prevention. Curr. Med. Chem. 2011, 18, 4866–4871. [Google Scholar] [CrossRef]
- Harris, T.; Bardien, S.; Schaaf, H.S.; Petersen, L.; De Jong, G.; Fagan, J.J. Aminoglycoside-induced hearing loss in HIV-positive and HIV-negative multidrug-resistant tuberculosis patients. S. Afr. Med. J. 2012, 102 Pt 2, 363–366. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Mwansasu, C.S.; Siziya, S.; Mpondo, B.C.T. Hearing Loss among Multi-Drug Resistant Tuberculosis patients on Kanamycin in Ndola Teaching Hospital, Zambia: Study of ototoxicity and practice. Health Press Zamb. Bull 2017, 1, 72. [Google Scholar]
- Nizamuddin, S.; Khan, F. Assessment of hearing loss in multi-drug resistant tuberculosis (MDR-TB) patients undergoing Aminoglycoside treatment. Int. J. Res. Med. Sci. 2015, 3, 1734–1740. [Google Scholar] [CrossRef] [Green Version]
- Sharma, V.; Bhagat, S.; Verma, B.; Singh, R.; Singh, S. Audiological evaluation of patients taking kanamycin for multidrug resistant tuberculosis. Iran. J. Otorhinolaryngol. 2016, 28, 203. [Google Scholar]
- Tiwari, M.; Kumar Roy, A.; Shamaliya, K.; Kumar Yadav, S. Ototoxicity Associated with The Usage of Injectable Kanamycin in Multi-Drug Resistant Tuberculosis Patientsduring Intensive Phase of Category IV Treatment on DOTS-Plus Therapy. IOSR J. Dent. Med. Sci. 2016, 15, 2279–2861. [Google Scholar] [CrossRef]
- Modongo, C.; Sobota, R.S.; Kesenogile, B.; Ncube, R.; Sirugo, G.; Williams, S.M.; Zetola, N.M. Successful MDR-TB treatment regimens including amikacin are associated with high rates of hearing loss. BMC Infect. Dis. 2014, 14, 542. [Google Scholar] [CrossRef] [Green Version]
- Brits, J.; Strauss, S.; Eloff, Z.; Becker, P.J. Hearing profile of gold miners with and without tuberculosis. Occup. Env. Med. 2012, 69, 243–249. [Google Scholar] [CrossRef]
- Human, H.; Hagen, C.M.; de Jong, G.; Harris, T.; Lombard, D.; Christiansen, M.; Bardien, S. Investigation of mitochondrial sequence variants associated with aminoglycoside-induced ototoxicity in South African TB patients on aminoglycosides. Biochem. Biophys. Res. Commun. 2010, 393, 751–756. [Google Scholar] [CrossRef]
- Sha, S.-H.; Taylor, R.; Forge, A.; Schacht, J. Differential vulnerability of basal and apical hair cells is based on intrinsic susceptibility to free radicals. Hear. Res. 2001, 155, 1–8. [Google Scholar] [CrossRef]
Frequency Band (kHz) | Signal to Noise Ratio (dB) | Reproducibility (%) |
---|---|---|
1.5 | ≥+3 | ≥50 |
2.0 | ≥+6 | ≥70 |
3.0 | ≥+6 | ≥70 |
4.0 | ≥+6 | ≥70 |
Demographic Variable | Treatment Group | Control Group | Total | ||||
---|---|---|---|---|---|---|---|
n | % | n | % | n | % | ||
Gender | Male | 27 | 45 | 27 | 45 | 54 | 45 |
Female | 33 | 55 | 33 | 55 | 66 | 55 | |
Age (years) | 18–29 | 13 | 23 | 22 | 36 | 35 | 29 |
30–39 | 18 | 30 | 19 | 32 | 37 | 31 | |
40–50 | 29 | 48 | 19 | 32 | 48 | 40 | |
TB Type | ETB | 11 | 18.3 | 11 | 18.3 | ||
PTB | 49 | 81.7 | 49 | 81.7 | |||
Total | 60 | 100 | 60 | 100 | |||
HIV Status | Positive | 6 | 10 | 6 | 10 | ||
Negative | 54 | 90 | 54 | 90 |
Variable | Treatment Group | ||
---|---|---|---|
Number (n) | Percentage (%) | ||
Cases | New | 46 | 76.7 |
Retreatment | 14 | 23 | |
Total | 60 | 100 | |
Phases | First phase | 20 | 33.3 |
Last phase | 40 | 66.7 | |
Treatment duration | 1–2 months | 18 | 30 |
3–4 months | 18 | 30 | |
5–6 months | 11 | 18.3 | |
7–8 months | 12 | 20 | |
9–12 months | 1 | 1.7 |
Bone Conduction Thresholds dBHL | ||||
---|---|---|---|---|
Treatment Group | ||||
Frequency (Hz) | Ears | Maximum | Minimum | Mean ± SD |
500 | Right Left | 30 35 | 15 15 | 22.50 ± 5.87 22.50 ± 6.91 |
1000 | Right Left | 40 30 | 15 15 | 26.67 ± 7.79 25.83 ± 6.34 |
2000 | Right Left | 40 40 | 10 25 | 29.17 ± 7.64 32.50 ± 4.52 |
4000 | Right Left | 55 55 | 30 30 | 37.50 ± 8.39 39.17 ± 9.25 |
Air Conduction Thresholds dBHL | |||||||
---|---|---|---|---|---|---|---|
Treatment Group | Control Group | ||||||
Freq (Hz) | Ears | Maximum | Minimum | Mean ± SD | Maximum | Minimum | Mean ± SD |
250 | Right Left | 30 30 | 5 5 | 15.67 ± 6.28 16.92 ± 5.62 | 25 25 | 5 5 | 15.33 ± 5.44 17.00 ± 4.71 |
500 | Right Left | 30 30 | 5 5 | 15.63 ± 6.30 17.33 ± 5.46 | 25 25 | 5 10 | 15.33 ± 5.81 16.67 ± 4.19 |
1000 | Right Left | 40 30 | 5 5 | 16.79 ± 7.24 16.75 ± 6.07 | 25 25 | 5 5 | 16.17 ± 5.92 16.58 ± 4.74 |
2000 | Right Left | 40 45 | 5 5 | 15.83 ± 7.54 16.79 ± 7.12 | 25 25 | 5 5 | 15.00 ± 6.18 15.33 ± 4.86 |
3000 | Right Left | 45 45 | 0 5 | 17.21 ± 8.09 17.46 ± 8.10 | 25 25 | 5 5 | 15.75 ± 6.16 16.67 ± 4.84 |
4000 | Right Left | 60 55 | 0 0 | 17.25 ± 9.99 18.25 ± 9.61 | 25 25 | 0 5 | 15.58 ± 5.83 17.58 ± 4.56 |
6000 | Right Left | 80 75 | 0 0 | 17.92 ± 11.4 18.88 ± 11.1 | 25 25 | 0 5 | 15.83 ± 6.19 16.92 ± 4.97 |
8000 | Right Left | 80 80 | 5 0 | 18.71 ± 12.3 19.58 ± 11.7 | 25 25 | 5 0 | 15.75 ± 6.02 18.33 ± 5.94 |
Hearing THRESHOLD Parameter (Hz) | Ear | Treatment Group Mean ± SD | Control Group Mean ± SD | p-Value |
---|---|---|---|---|
2000, 3000, 4000 | Right Left | 18.68 ± 9.03 18.93 ± 9.60 | 15.70 ± 4.093 15.90 ± 3.740 | 0.021 0.024 |
500, 1000, 2000 | Right Left | 16.95 ± 6.98 17.70 ± 6.53 | 15.50 ± 3.96 16.17 ± 3.45 | 0.164 0.111 |
Variable | Normal Audiometry Findings | Abnormal Audiometry Findings | χ2 | df | p-Value | ||
---|---|---|---|---|---|---|---|
n | % | N | % | ||||
On medication | 48 | 44.4 | 12 | 100 | 13.33 | 1 | 0.000 |
No medication | 60 | 55.6 |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Owusu, E.; Amartey, B.T.; Afutu, E.; Boafo, N. Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana. Diseases 2022, 10, 10. https://0-doi-org.brum.beds.ac.uk/10.3390/diseases10010010
Owusu E, Amartey BT, Afutu E, Boafo N. Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana. Diseases. 2022; 10(1):10. https://0-doi-org.brum.beds.ac.uk/10.3390/diseases10010010
Chicago/Turabian StyleOwusu, Enid, Benjamin T. Amartey, Emmanuel Afutu, and Neal Boafo. 2022. "Aminoglycoside Therapy for Tuberculosis: Evidence for Ototoxicity among Tuberculosis Patients in Ghana" Diseases 10, no. 1: 10. https://0-doi-org.brum.beds.ac.uk/10.3390/diseases10010010